Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siegfried Wassenberg

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Rheumatology and Therapy|May 6, 2017
Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Arthritis and Rheumatism|November 1, 2006
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trialsAngela Zink, Anja Strangfeld, Matthias Schneider, et al.
RMD Open|November 5, 2015
Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012Dörte Huscher, Katja Thiele, Martin Rudwaleit, et al.
Trials|October 29, 2014
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trialJacqueline Detert, Pascal Klaus, Joachim Listing, et al.
Rheumatology International|August 9, 2011
Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studyStefan Kleinert, Hans-Peter Tony, Andreas Krause, et al.
RMD Open|May 7, 2026
Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysisAndriko Palmowski, Tobias Haugegaard, Ingiäld Hafström, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational studyFrank Behrens, Gerd-Rudiger Burmester, Michael W Hofmann, et al.
The Journal of Rheumatology|January 6, 2006
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitisAngela Zink, Katja Thiele, Doerte Huscher, et al.
RMD Open|July 3, 2021
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Jacqueline Detert, Rolf Rau, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Rheumatology and Therapy|May 6, 2017
Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Arthritis and Rheumatism|November 1, 2006
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trialsAngela Zink, Anja Strangfeld, Matthias Schneider, et al.
RMD Open|November 5, 2015
Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012Dörte Huscher, Katja Thiele, Martin Rudwaleit, et al.
Trials|October 29, 2014
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trialJacqueline Detert, Pascal Klaus, Joachim Listing, et al.
Rheumatology International|August 9, 2011
Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studyStefan Kleinert, Hans-Peter Tony, Andreas Krause, et al.
RMD Open|May 7, 2026
Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysisAndriko Palmowski, Tobias Haugegaard, Ingiäld Hafström, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational studyFrank Behrens, Gerd-Rudiger Burmester, Michael W Hofmann, et al.
The Journal of Rheumatology|January 6, 2006
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitisAngela Zink, Katja Thiele, Doerte Huscher, et al.
RMD Open|July 3, 2021
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Jacqueline Detert, Rolf Rau, et al.
Pageof 5